Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · IEX Real-Time Price · USD
9.47
+0.62 (7.01%)
At close: May 16, 2024, 4:00 PM
9.53
+0.06 (0.63%)
After-hours: May 16, 2024, 7:31 PM EDT
Company Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions.
It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc.
Country | United States |
Founded | 1995 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 16 |
CEO | Dr. Jerel A. Banks M.D., Ph.D. |
Contact Details
Address: Level 14, 114 William St Melbourne Vic, C3 3000 Australia | |
Phone | 3 8692-7222 |
Website | benitec.com |
Stock Details
Ticker Symbol | BNTC |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001552795 |
CUSIP Number | 08205P100 |
ISIN Number | US08205P2092 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Jerel A. Banks M.D., Ph.D. | Executive Chairman and Chief Executive Officer |
Megan Joan Boston BComm, CA, Dip., GAICD | Executive Director |
Dr. Michael Graham | Head of Discovery and Founding Scientist |
Dr. Claudia Kloth | Senior Vice President of Manufacturing |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 27, 2020 | 15-12B | Securities registration termination |
Apr 16, 2020 | EFFECT | Notice of Effectiveness |
Apr 16, 2020 | EFFECT | Notice of Effectiveness |
Apr 15, 2020 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Apr 15, 2020 | POS AM | Post-Effective amendments for registration statement |
Apr 15, 2020 | POS AM | Post-Effective amendments for registration statement |
Apr 15, 2020 | 6-K | Report of foreign issuer |
Apr 14, 2020 | 25 | Filing |
Apr 14, 2020 | 25-NSE | Filing |
Apr 3, 2020 | 6-K | Report of foreign issuer |